Review Article

Translational research: current status, challenges and future strategies

Dale Yu

Hoffmann-La Roche Inc. 340 Kingsland Street, Nutley, New Jersey 07110-1199, USA.

Received July 26, 2011; accepted August 29, 2011; Epub September 12, 2011; Published October 31, 2011

Abstract: Advances in translational research are expected to mitigate the recent drought in new drug development. Despite significant progress recently made in biological sciences, the results are decidedly mixed with significant breakthrough in some disease areas while extensive work remains to be completed in other areas. This review article provides a general survey of the current landscape of translational research so as to identify progress and areas of needs and the associated strategy. While significant advances in the development of translational tools have been made in all fronts, the availability of predictive preclinical models remains critical for the success of translational research. This is directly correlated with the success of translational research as illustrated by the recent approval of targeted drug therapies. By the same logic, unexpected side effects can also be explained by laboratory findings, thus completing the translational cycle. Because of this reason, further collaboration between preclinical and clinical scientists is essential. Non-scientific issues have important influence on the future of this endeavor cannot be underestimated either. Nonetheless, with definitive commitment of private industry and public resources, the future of translational research is promising.

Keywords: Translational medicine, review, policy, government regulation, cancer, cardiovascular disease, renal disease, HIV/AIDS, skin disease, tools

Introduction

Advances in translational research are expected to facilitate the development of safe and efficacious drug therapies in the 21st century. Despite significant progress recently made in biological sciences, the results are decidedly mixed. Continuing on this journey, a review of successes and hurdles could help identify the areas of needs and strategies. This article is intended to review the general landscape of translational research from the perspectives of strategy, processes, tools, actual successes, unrealized goals, and challenges. While this summary is not intended to be comprehensive, a survey does illustrate significant progress in drug therapies in some disease areas. This author hopes that this article could generate additional interest in the translational research community and promote further inter-discipline collaboration that results in improved patient care.

Traditional translational research processes

Preclinical investigation

In the first step of discovering new drug therapies, in vitro model systems of cell and tissue preparations are frequently used to elucidate the etiology/pathogenesis of disease states based on which the hypotheses for possible therapies are developed. Experiments are then conducted to examine novel therapeutic strategies that might interfere with these pathologic processes. This is followed by examining potential drug effects in more complex systems including animal disease models. The closer the animal model resembles the pathophysiology of the human disease, the more likely is the model predictive of the human response to an intervention. Unfortunately, many diseases have no good animal models and safety and efficacy can only be properly assessed in patients with the target disease. This underscores the uncertainty of the predictive value of animal data [1, 2].

Clinical investigation

Initial human experimentation, also referred to as Phase I or human pharmacology testing, is usually performed in healthy volunteers [3]. If the accumulated safety and laboratory data support further human investigations, Phase II or therapeutic exploratory testing (proof of con-
cept study) is conducted in the target disease patient population to provide a further assessment of safety as well as potential efficacy across a range of doses. The vast majority of compounds tested in Phase I and II studies fail to progress to Phase III testing because of safety concerns, lack of efficacy, or both. These problems, although discouraging, are to be expected. What is more disconcerting are the number of agents that are well tolerated, but fail to provide efficacy in clinical trials despite compelling laboratory efficacy evidence [2]. An incomplete understanding of the disease states and the impact of treatment modalities is frequently the cause of this type of failures.

Private industry and government initiatives

Recognizing the challenge, the pharmaceutical industry has recently been focusing on translational research actively. The academic medical research community has similarly embraced this paradigm largely through the motivation of National Institute of Health (NIH) via its Roadmap initiative. The NIH concludes that barriers between clinical and basic research, along with increased complexities in conducting clinical research, are making it more difficult to translate new knowledge to the clinic - and back again to the bench. In collaboration with the academics and research community, the NIH launched the Clinical and Translational Science Awards (CTSA) Consortium in 2006 with the plan of linking approximately 60 institutions to energize the discipline of clinical and translational sciences. The primary goal of the CTSA Programs is to assist institutions to forge an integrative academic home for Clinical and Translational Science. By consolidating resources, this consortium hopes to promote multi- and inter-disciplinary clinical and translational research so that new knowledge and techniques will become more readily available to patient care. Operationally, the members of the CTSA consortium are to attract basic, translational and clinical investigators, community clinicians, clinical practices, networks, professional societies, and industry together to form new professional interactions, programs, and research projects. These new institutional arrangements, coupled with innovative advanced academic degree programs, are to foster the new discipline of Clinical and Translational Science that will be broader and deeper than the classical and separate domains of translational research and clinical investigation [4]. As this is a fairly new initiative, the impact may not be immediately apparent until decades later.

Available tools

Currently, translational biology, predictive toxicology, in vitro-in vivo extrapolation, quantitative pharmacology, biomarkers, and surrogate endpoints are the translational research tools that are commonly used in the scientific community. A summary of these different approaches is provided in the following sections.

Translational biology

The microarray technology is enabling scientists to simultaneously investigate the expression of thousands of genes. Basic scientists and clinical investigators appreciate the great potential of this technology, not only for gaining new insights into cell biology and ultimately for developing a more biologically sound and clinically useful classification, but also for improving the management of a myriad of different diseases, with cancer being one of the important focuses. Other important technology platforms are available to analyze genetic and epigenetic changes in DNA, microRNAs, proteins and functional proteins. Ultimately, the use of all these platforms should help develop a much more comprehensive picture of the biology of diseases, as well as the variability in responses between patients [5].

Humanized mice overcomes the ethical and technical constraints of studying human biology in vivo that would otherwise not be possible [6]. This genetically engineered mouse model has been applied to the study of pancreatic cancer, brain tumors, leukemia, prostate cancer programmed cell death mechanisms, and rational chemotherapy [7].

Predictive toxicology

Liver and the cardiovascular system often give rise to safety related drug attrition. The highest incidence of concordance between animal and human toxicities is commonly observed for the cardiovascular, gastrointestinal, and hematological effects of drugs. The isolated, paced Langendorff-perfused female rabbit heart model provides detailed information on the overall profile of drug-induced electrophysiological ef-
fects and allows drugs to be classified based on their action potential morphology and conduction properties [8]. Dog telemetry is the standard in vivo study used to assess cardiovascular liability. These animal studies are often required to support human testing and registration.

The liver is the first point of contact of a drug following oral absorption, and drug-related idiosyncratic toxicity is still one of the major causes of acute liver failure cases in human. High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity has been reported via the high content screening technology in man [9].

**In vitro–in vivo extrapolation**

Computer program like Simcyp® links in vitro and early human study data by predicting the systemic drug exposure in humans. This facilitates the “go–no go” decisions in drug discovery and development [10]. Systems biology computer simulation tools like CellDesigner, COPASI and VirtualCell, are used to facilitate translational research in genomics, proteomics and systems biology [11].

**Pharmacokinetic-pharmacodynamic (PK-PD) modeling and simulation**

PK-PD links drug concentration to a temporal biological effect profile over time. Translating these measurements from animals to man is the key to successfully reducing attrition in drug development. Animal and human PK-PD experiments are conducted to predict efficacy or side effects [10]. Thoughtful planning and quantitatively based decision making have increased the chance of successful drug treatment, and when failure occurs the root cause is more readily understood [12].

**Biomarkers**

Biomarkers can be used for diagnosis, prognosis, selection of patient therapy, and for providing insights in disease mechanism and progression [13]. The enormous biological variability among individual patients, as well as the huge dynamic range of biomarker concentrations present the main challenges to deduce diagnostic patterns that are unique to specific disease states [14]. To determine if a biomarker can offer prognostic-predictive or predictive clinical utility, a prospective or retrospective exploratory analyses of clinical study data could be performed. This could be followed by a validation step in a well designed randomized controlled clinical trials [15].

**Recent clinical successes and setbacks in translational research**

Important progress has been made recently in therapeutic area like oncology as a result of successful translational research. On the other hand, limitations and hurdles that require extensive research are also quite clear in disease like Alzheimer’s, nicotine dependence, and neural repair due to a lack of predictive animal model. In other cases, new translational technology tool like functioning MRI and a better understanding of the mechanisms of pathogenesis are now available which could set the foundation for future breakthrough.

**Oncology**

**DNA repair**

Exaggerated environmental exposures of polyvinyl compounds, sunlight, nicotine, diet, polycyclic aromatic hydrocarbons, alkyl amines, arsenic, and chromium could induce DNA damage that may not be adequately repaired and could represent an early step in the pathogenesis of disease. Among the familial diseases, defective DNA repair pathways have been reported in xeroderma pigmentosum (XP), hereditary non-polyposis colon cancer, and hereditary breast cancer, among others [16]. Topical application of the T4 DNA glycosylase repair enzyme in liposomes reduced the 1-year appearance of skin tumors in XP patients which led to the FDA approval of Dimericine®, a “DNA repair drug” for XP and severe skin-burn patients [17].

**Monoclonal antibody treatment**

The approval of bevacizumab (Avastin®) and trastuzumab (Herceptin®) by the FDA and the European Community also represents a recent successful example of translational research. Bevacizumab and trastuzumab are monoclonal antibodies that bind specifically to proteins critical to cancer cell growth and are examples of targeted therapy. Trastuzumab targets human epidermal growth factor receptors highly expressed in up to 25% of metastatic breast can-
cers [18]. It reduced tumor progression and prolonged survival in those patients with human epidermal growth factor R2 positive metastatic cancer [19]. Bevacizumab targets vascular endothelial growth factor and blocks the binding of this potent, pro-angiogenic factor to tumor vasculature, thereby inhibiting tumor blood supply and growth. When used in patients with metastatic colorectal cancers, bevacizumab inhibited tumor growth and improved survival [20, 21]. The discovery, sequencing, and cloning of the human epidermal growth factor receptor back in 1985 was a critical first step [22]. Subsequent advances in molecular biology, in particular proteomics, led to the synthesis of human antihuman epidermal growth factor antibodies for use in clinical trials. Successful transition through phase II and III trials resulted in its approval for human use in 2000 [18, 23].

**Targeted gene therapy**

Advances in antisense methods targeting genes involved in cell proliferation, angiogenesis, and apoptosis could interfere with cancerous growth. For example, gefitinib (Iressa®) inhibits the intracellular phosphorylation of numerous tyrosine kinases associated with transmembrane cell surface receptors, including those associated with the epidermal growth factor receptor (EGFR-TK). EGFR is expressed on the cell surface of many normal cells and cancer cells and a subset of patients that possess activating mutations in the EGFR was most responsive to gefitinib [24, 25].

Continuous technological advances in genomics, proteomics, genetics, and epigenetics are continuing to provide new insights into oncogenic pathways, DNA repair, stem cells, metabolism, and the tumor microenvironment. This is augmented by advances in animal and quantitative models of cancer which leads to novel approaches to cancer prevention, therapy, and progress in individualizing cancer treatment [26].

**Neurology**

**Alzheimer's disease**

Alzheimer's disease (AD) is the most prevalent form of dementia and the number of cases is expected to increase exponentially worldwide. To date, three identified highly penetrant genes (AbetaPP, PSEN1, and PSEN2) can explain only a small number of AD cases with a Mendelian transmission pattern. Many genes have been analyzed for association with non-Mendelian AD, but the only consistently replicated finding is apolipoprotein E (APOE). At the present, the possibilities for prevention, early detection, and treatment of the disease are limited and APOE genotyping is not considered useful for screening, presymptomatic testing, or clinical diagnosis of non-Mendelian AD. Most research on genome-based applications in AD is still in the first phase of the translational research which means that extensive work is still needed before a new treatment modality is feasible [27].

**Migraine and pain**

During episodes of migraine attack and pain, functional brain imaging is now used to study activity within the brain as a translational technology. Specifically, the brain patterns of activation alongside responses to thermal and mechanical stimuli are evaluated and compared between healthy individuals and patients [28, 29]. Therefore, functional MRI can be used preclinically to define functional pain pathways and activation signatures for therapeutically useful drug therapies. This tool can highlight pathways that may be sensitive to pharmacological or behavioral therapeutic intervention within the brain during pain [30].

**Nicotine dependence**

Dependence on psychoactive substances including illicit drugs, alcohol or nicotine continues to exact a heavy burden on the health and welfare of users and on society. A major obstacle to the development of medications for nicotine dependence is that the current animal and human laboratory models have limited predictive clinical validity. Despite common underlying CNS circuitry, drug effects might manifest in different behaviors in animals and humans. Looking to the future, using imaging to develop profiles of neural activation corresponding to particular dimensions of dependence — might be helpful in determining behavioral model validity and in medication development [31].

**Insomnia**

Insomnia is a common and disabling complaint for which there is a need for improved treat-
ments. Caffeine administration is a simple and effective model of the difficulty in initiating sleep in both rats and humans. Interestingly, it’s stimulatory effects are sensitive to sleep-promoting agents including zolpidem (Ambien®) and trazodone (Desyrel®) which have different mechanisms of action. Collectively, these data provide a potentially predictive translational model of onset-to-insomnia. The model could provide a quick and simple way to evaluate the likelihood of success of a new treatment [32].

**Neural repair**

Clinicians seeking interventions for neural repair in patients with paralysis and other impairment have traditionally extrapolated the results of cell culture and rodent experiments into the framework of a preclinical study. The various rodent models of repair for stroke and spinal cord injury still lack information that identifies key considerations of the disease. These included the lesion of etiology, volume and location that reflects the human disease; examine changes induced by injury and by repair procedures both near and remote from the lesion; and etc [33]. Similar to AD, extensive research work is still needed in pursuing neural repair.

**Anesthesia**

Even though anesthetic care during a surgical intervention is remarkably safe, further advances is needed to address clinical problems in the risky perioperative period. Paraplegia is a complication that occurs in 3%–16% of thoracic and thoraco-abdominal aneurysm repair which could be associated with an increase in mortality and a reduction in the quality of life [34-36]. Recent translational research work discovered that the μ and δ opioid receptor agonists facilitate the release of the excitatory neurotransmitter, glutamate, which triggers excitotoxic cell death via stimulation of N-methyl d-aspartate receptors on inhibitory interneurons in the ventral horn of the spinal cord, thereby causing spastic paraparesis [37]. This is a good example how the feedback of clinical findings led to laboratory research that could offer a treatment solution in the future.

**Focal cortical dysplasia**

Cortical dysplasia (CD) are the pathological substrates in a large percentage of patients with pharmaco-resistant epilepsy who may be amenable to surgical treatment. Although genetic models that clearly mimic human malformations are still limited, some models seem to reproduce some rare dysplastic pathologies. Difficulties encountered in the studying of such models are the determination of how mutations in diverse sets of genes ultimately lead to alterations in brain excitability [38]. Other animal models were not able to establish an association between pathology and electrophysiology findings.

Further research is needed to determine how transformation of various models of “dormant” pathology into an active (spontaneous) epileptic pathologies. These studies should reproduce some of the features that are characteristic of the natural history of some forms of human pathology and would ultimately lead to the identification of some of the cellular mechanisms of epileptogenesis and the future design of “preventative” interventions [39].

**Amyotrophic lateral sclerosis (ALS)**

Amyotrophic lateral sclerosis (ALS) is a clinically severe and fatal neurodegenerative disease characterized by a loss of both upper and lower motor neurons, resulting in progressive muscle loss and paralysis. While the exact cause of neuronal death in ALS remains unknown, multiple molecular defects were theorized to trigger motor neuron cell death. These pathophysiological mechanisms include oxidative stress, mitochondrial impairment, protein aggregation, glutamate cytotoxicity, transcription dysfunction, inflammation, and apoptotic cell death. An important advance in clinical trials in ALS patients has been the introduction of genetic mouse models of ALS [40, 41]. The phenotypes of ALS transgenic rodent models appeared to highly correlate with human neurological disease by providing parallel pathophysiological targets that are also present in ALS patients which may validate the known CNS drug targets in a therapeutically relevant manner.

While drug trials in mice confirm therapeutic direction, a more definitive understanding of the molecular events leading to motor neuron death in ALS still remains to be elucidated. Specific neuroprotective strategies targeted at identified molecular mechanisms have the potential to dramatically delay the onset and slow the pro-
progression of ALS. As such, compounds like creatinine, Coenzyme Q10, histones, riluzole, rasagiline, minocycline and etc. could emerge as relatively safe therapeutics for the treatment of ALS. As the drug agents and their analogs described here are already available for human use, combine neuroprotective therapies may reach greatest efficacy due to the multiple levels of molecular pathology and treatment [42].

Cardiovascular disease

Toxicity resulting from drug treatments

Trastuzumab

Translational medicine has been used less frequently in the development of cardiovascular drugs or in predicting potential cardiovascular toxicity of non-cardiac agents. As described in the Oncology section, trastuzumab, a humanized monoclonal antibody acts against the proto-oncogene HER2, a receptor in the epidermal growth factor family that is amplified in many patients with breast cancers. When the HER2 gene was conditionally deleted in the mice heart, mice displayed no overt phenotype and survived to adulthood. However, the mice hearts showed morphologic and hemodynamic changes consistent with dilated cardiomyopathy and they were unable to tolerate the stress of increased load or administration of an anthracycline [43].

Trastuzumab's action against HER2 could now explain why it was associated with a 500% (4.1% versus 0.8%) relative increase in the incidence of left ventricular dysfunction in one study and a 6.6% absolute incidence of cardiac dysfunction in a second study in patients with early-stage breast cancer [44, 45]. Therefore, the challenge now is to translate the available basic science data into rationale use of this agent, particularly in that population of patients without metastatic disease [46].

COX-2 inhibitors

Another group of compounds that have been associated with unexpected cardiovascular toxicity are the inhibitors of prostaglandin (PG) endoperoxide synthases (cyclooxygenases) or COXs [47, 48]. COXs oxygenate arachidonic acid to form a wide array of products including a family of PGs and thromboxane A2. These products have conflicting cellular effects as PGI2, PGE1, and PGD2 inhibit platelet aggregation by activating adenylyl cyclase, whereas thromboxane A2 facilitates platelet aggregation and vasoconstriction; the role of these pathways in any tissue being mitigated by the presence and number of selective PG or thromboxane receptors [49]. There is experimental evidence that inhibition of the COX-2 gene is associated with increased cardiac [50] and pulmonary fibrosis [51], whereas deletion of one allele of COX-2 resulted in enhanced cardiac damage in mice with viral myocarditis [52]. Inhibition of COX-2-dependent pathways in the genetic mouse models also predisposes mice to an exaggerated response to thrombotic stimuli [53], increases blood pressure [54], facilitates an enhanced proliferative response to vascular injury [55], and accelerates atherogenesis [56]. Nonetheless, the effects of selective COX-2 inhibition can be modified by genetic background, gender, and disease state [57]. Thus, additional basic science data is needed to identify the genetic and phenotypic profile of patients that have a higher likelihood of developing an adverse response to the COX-2 inhibitors [49].

Restenosis

Numerous approaches to reduce the rates of restenosis were studied between 1988 and 2000 have been disappointing [58]. Regulating cell proliferation is essential to treating restenosis. Activation of regulatory enzyme sub-units known as cyclins can inhibit proliferation and without compensatory pathways exists, suitable drug therapy should be highly efficacious. For example, sirolimus indirectly elevates cyclin p27 concentrations which in turn inhibit the proliferation and migration of smooth muscle cells. A recent clinical trial result confirmed that sirolimus-eluting stents were able reduced restenosis in diabetic patients [59, 60].

In addition to drug therapy, regenerative biology and replacement therapy have been pursued together with the study of genomics and proteomics, embryo genesis, immunobiology, inflammation, thrombosis, public health, and health promotion [61]. However, the results of clinical trials in myocardial regeneration therapy have been relatively disappointing. Additional mechanistic laboratory studies are still needed on how the transplanted cells are transformed and what signaling pathways are modified. The
combined use of different cell types, cells in various stages of activation or differentiation, or both, might lead to improved myocardial regeneration [62].

**Cardiomyopathy**

Dilated cardiomyopathy (DCM) is the third cause of heart failure (HF) and is characterized by progressive ventricular dilation and functional impairment in the absence of coronary lesions and/or hypertension. An accurate large animal model of DCM is pacing-induced HF. It is obtained by continuous cardiac pacing at a frequency three- to fourfold higher than the spontaneous heart rate and is mostly applied to dogs, but also to pigs, sheep and monkeys. To date, this model is considered a gold standard in HF research. A wide variety of other animal models of HF is available to study DCM and to test innovative diagnostic procedures and therapeutic strategies. However, none of these animal models can entirely reproduce the human disease. Based on the analysis of a working group convened by the National Heart, Lung, and Blood Institute, testing promising interventions in large mammals and conscious preparations is recommended [63, 64].

**Renal disease**

**Glomerular injury**

In recent years, research into the role of complement in the immunopathogenesis of renal disease has broadened the understanding of the fragile balance between the protective and harmful functions of the complement system. Interventions into the complement system in various models of immune-mediated renal disease have resulted in both favorable and unfavorable effect and will help define the level of the complement cascade at which a therapeutic intervention will result in an optimal effect. The discovery of mutations of complement regulatory molecules has established a role of complement in the hemolytic uremic syndrome and membranoproliferative glomerulonephritis, and genotyping for mutations of the complement system are already moving from the research laboratory into clinical practice. These clinical discoveries have resulted in the creation of relevant animal models which may provide crucial information for the development of highly specific therapeutic agents. Research into the role of complement in proteinuria has facilitated the understanding of inflammation pathways which ultimately lead to renal failure irrespective of the underlying renal disease and is of major importance for the majority of renal patients. Complement science is expected to result in meaningful therapeutic advances in the near future [65].

**Other diseases**

**HIV/AIDS**

The new antiretroviral, maraviroc, is a CCR5 fusion inhibitor. Based on the clinical experience to date, this agent looks promising as an option for treatment-experienced patients [66]. This agent blocks the binding between glycoproteins on the outer coat of HIV and receptors of these glycoproteins of CD4 cells. These results were later confirmed by the proof-of-concept studies in animals [67]. Depleting the latent reservoir of HIV is another attractive hypothesis based on which substantial research laboratory work is being conducted [68].

**Corneal epithelial wound healing**

Basic research on the mechanism of corneal epithelial wound healing has the potential to lead to the development of new modes of treatment for persistent corneal epithelial defects. Fibronectin is expressed at the site of corneal epithelial defects, serves as a provisional matrix for the migration of epithelial cells, and stimulates epithelial wound healing in vitro and in animal models. Eyedrops containing autologous plasma fibronectin are also effective for the treatment of persistent epithelial defects of the cornea in patients. Substance P and insulin-like growth factor-1 synergistically stimulate corneal epithelial wound healing in vitro and in animal models. Furthermore, the administration of eye drops containing both a substance P-derived peptide (FGLM-amide) and insulin-like growth factor-1-derived peptide (SSSR) were effective in the treatment of persistent epithelial defects in individuals with neurotrophic keratopathy [69].

**Surgical disease**

Recent translational research in surgical diseases includes investigations in thyroid nodule diagnosis, treatment for gastrointestinal stromal
tumors (GIST) and colon cancer, aortic aneurysm treatment, mathematical models for kidney donor–recipient matching, and breast cancer treatment [70]. One of the earliest success stories of targeted molecular therapies in cancers arose among a subset of soft-tissue sarcomas referred to as GIST. These are rare tumors but comprise one of the common mesenchymal tumors of the gastrointestinal tract. In 2001, a patient with metastatic GIST tumor was successfully treated with imatinib (Gleevec®), a selective small-molecule inhibitor of the KIT (CD117) proto-oncogene [71]. The specific type of mutation in C-KIT determines the response to therapy to imatinib. Mutations in exon 11 of C-KIT were observed in approximately 70% of GIST cases and are associated with a response rate of 85%. However, patients with mutations in exon 9 of C-KIT was observed in about 17% of GIST which had a much lower response rates of only 45%. Patients with no mutations have no response. Unfortunately, most patients eventually develop resistance to imatinib with long-term therapy but, based on the success of this targeted therapy, other targeted therapies have since been developed. Sunitinib (Sutent®), a multi-target tyrosine kinase inhibitor, has now been developed and was approved by the Food and Drug Administration for use in patients who have an imatinib-resistant GIST or are intolerant to GIST [72].

Psoriasis

Psoriasis is perhaps unique for a disease that there is still no acceptable animal model despite many rounds of bi-directional translation research. The course of discovery that led to introduction of targeted biologics for psoriasis depended heavily on fundamental discoveries in basic science laboratories of immunological pathways. Subsequently, antibodies or fusion proteins to specific immune molecules have proved to be effective in models of inflammation or organ transplantation and ‘humanized’ molecules were created, but few were intended for psoriasis as the main indication.

Fortunately, the relevant pathways had been expressed in psoriasis lesions and many, but not all, of the intended therapeutics do have positive activity in patients with psoriasis. The currently approved biologic therapeutics mostly followed this pathway of discovery and implementation, while at the same time provide some new insights into disease biology. These therapeutics include T-cell blocker like efalizumab (Raptiva®) and tumor necrosis factor (TNF) alpha blocker like etanercept (Embrel®). While many of these new biologic therapies seem to have favorable safety profiles and may offer better long-term disease management than the older conventional agents, important information still remains to be gathered about the functional consequences of blocking specific immune molecules and pathways in humans. Future work should strive to learn more about the specific effects of new therapeutic agents on the human immune system [73].

Challenges and future strategies

So far, this review has described the current translational research strategy, process, and tangible results. While great challenges do exist, they have proven not to be insurmountable. Some challenges and mitigating strategies are summarized in the following sections.

Validation of clinically useful biomarkers

The discovery of clinically useful biomarkers is critical to the success of translational research but few such new tests have appeared to date [74]. In laboratory medicine, the transfer of promising research assays to daily laboratory practice could take years and involves many tedious and sequential steps. This difficulty is often related to methodological biases in animal experimentation and differences between animal and human pathophysiology. In addition, there is a serious concern regarding the reliability and reproducibility of results because of sample handling and pre-analytical variability. Therefore, the most feasible and standardized collection procedures should be established before results of a novel and promising diagnostic technique can be transferred to daily laboratory practice [75, 76].

Limitations of preclinical and clinical study results

The preclinical “proof-of-concept” study is a critical step of translational research. Data variability and bias in interpretation are the principal challenges in designing, conducting, and analyzing preclinical studies. To detect the consequences of an intervention, the effect size must overcome the inherent variability in the model.
Small studies are especially sensitive to the effects of missing data; the inclusion or exclusion of a single data point can alter the results and conclusions of a study. Thus, a prospective plan to deal with missing data and outliers is essential. Animal deaths and the handling of missing data along with outliers should be discussed with the study results, where applicable. Multiplicity in statistical testing is often an issue in preclinical studies that is inadequately addressed [77].

Clinically, the current approach of treating broad populations of patients using a singular approach is not well suited to the development of molecularly targeted drugs considering the inherent inter-subject variability in drug response. Although developing drugs with individual patient focus is immensely more complex, it should improve the success rate of development, as well as provide benefit to patients and ultimately to the economics of healthcare [78].

**Non-scientific factors**

Many non-scientific factors do have significant impact on translational research. The availability of funding, conflict of interest, regulatory burdens, right to privacy, fragmented infrastructure, shortage of qualified investigators and willing participants, incompatible databases, and lack of congressional and public support are important and real concerns. Optimized academia–industry partnership, where academia delivers trained researchers skilled in translational research and industry helps to sponsor those programs, consider alternative funding sources, reduce the cost of clinical investigation by decreasing unnecessary burdens, and increase public support for biomedical research spending could help alleviate some of these concerns [79]. As described before, both the private industry and the NIH initiatives could address these issues as well.

**Address correspondence to:** Dr. Dale Yu, Hoffmann-La Roche Inc. 340 Kingsland Street, Nutley, New Jersey 07110-1199 Tel: (949) 858-2280; E-mail: dale.yu@roche.com

**References**


Translational research - a review

6: 283–96.


[36] Kakinohana M, Nakamura S, Fuchigami T, Davison KJ, Marsala M and Sugahara K. The acti-vation of spinal N-methyl-daspartate receptors may contribute to degeneration of spinal mo-


Translational research - a review

lines for percutaneous transluminal coronary angioplasty); Society for Cardiac Angiography and Interventions. Circulation 2001; 103: 3019–41.


